Treatment Trials
Home Clinical Trials Treatment Trials
The cause of Alzheimer’s disease remains unclear for the vast majority of patients, so the Bryan ADRC has clinical trials that focus on different therapeutic targets.  It has long been known that amyloid, generated by cleavage of amyloid precursor protein, accumulates in the brain and is associated with dementia.  We currently sponsor clinical trials in patients with mild Alzheimer’s disease that examine the effect of inhibitors of amyloid cleavage on dementia progression. A study of a compound that has been shown to increase energy production in patients with Mild Cognitive Impairment is in development.  Another trial that will be ready for enrollment in early summer 2013 is examination of a compound to treat agitation in patients with moderate to severe Alzheimer’s disease.  We recently completed an early phase study of a modified virus that when injected into the brain promotes the synthesis of Nerve Growth Factor, which helps maintain neuronal growth.  Results of this safety study are not yet available.  Bryan ADRC investigators also work with the pharmaceutical industry to develop novel therapies that have not yet been extensively tested in man for both safety and efficacy in treating dementia.